Key Metrics for a HealthTech and MedTech Company to Raise a Series B Round in Europe in Today's Environment

Why It Matters

These tightened standards compress the pool of fundable mid‑stage companies, forcing founders to prove capital efficiency and regulatory readiness to secure Series B capital. The shift reshapes valuation dynamics across Europe, accelerating consolidation and favoring AI‑driven, compliance‑ready players.

Key Takeaways

• ARR $10‑30M for HealthTech, $5‑15M for MedTech, 80‑100% YoY growth
• Burn multiple ≤1.5× signals strong capital efficiency
• AI‑native platforms target $500K‑$1M ARR per employee
• Full MDR/IVDR and EU AI Act compliance required by May 2026
• Series B rounds now take 10‑12 months to close

Pulse Analysis

The 2026 European venture landscape has shed the “growth at any cost” mindset that defined the zero‑interest‑rate era. With global digital‑health funding slipping 6.6 % year‑over‑year and deal counts halving, investors are exercising disciplined capital allocation. In Europe, Q1 saw $1.2 billion deployed across 67 deals, pushing the average round to $21 million, while the time to close a Series B has stretched to ten‑to‑twelve months. This liquidity contraction, combined with $2.5 trillion of private‑equity dry‑powder seeking defensible assets, forces startups to demonstrate tangible, revenue‑generating value before they can attract capital.

Financial expectations have pivoted toward profitability metrics. The Rule of 40 now leans heavily on EBITDA, with best‑in‑class health‑tech firms delivering >150 % YoY revenue growth and net‑revenue retention above 120 % to justify 10‑14 × EBITDA multiples. Series B candidates must post $10‑30 million ARR in digital health or $5‑15 million in med‑tech, backed by 80‑100 % growth rates. Capital efficiency is quantified by the burn multiple, where ≤1.5× signals discipline; AI‑native platforms further differentiate themselves by generating $500 k‑$1 million ARR per employee, unlocking 15‑18 × EBITDA premiums.

Regulatory compliance has become the primary moat. Full MDR/IVDR certification and adherence to the EU AI Act’s high‑risk requirements, due by May 2026, are now prerequisites for Series B financing. Early reimbursement signals—such as Germany’s expanded DiGA listing or the UK’s NHAP—add commercial credibility and accelerate market penetration. Founders that align product roadmaps with these regulatory milestones, while delivering clear ROI for providers, are positioned to command higher valuations and navigate the protracted fundraising timeline. In this environment, evidence‑backed, AI‑enhanced solutions are the most attractive targets for both European and U.S. investors.